Last reviewed · How we verify
Suvorexant Tablets
Suvorexant Tablets, marketed by the Medical University of South Carolina, is a sleep disorder treatment with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from other treatments in the market. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Suvorexant Tablets |
|---|---|
| Sponsor | Medical University of South Carolina |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial of Suvorexant for Sleep in Children With Autism (PHASE2)
- A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) (PHASE3)
- Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors (PHASE4)
- Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms (PHASE1, PHASE2)
- Suvorexant and Sleep/Delirium in ICU Patients (PHASE4)
- Suvorexant for Treatment of AUD and PTSD (PHASE2)
- Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress (PHASE4)
- A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |